NCCN Clinical Recommendations
NCCN Biomarkers Compendium™
On December 4, 2012, NCCN announced the availability of
the NCCN Biomarkers Compendium™–a tool developed to
identify the appropriate use of biomarkers to screen, diagnose,
monitor, and provide predictive and prognostic information for
the treatment of patients.
Based directly on the NCCN Guidelines, the NCCN Biomarkers
Compendium contains information designed to support decision-
making around the use of biomarker testing in patients with cancer.
The goal of the NCCN Biomarkers Compendium is to provide
essential details for those tests which have been approved by
NCCN Guidelines Panels and are recommended by the NCCN
Guidelines. Tests that measure changes in genes or gene
products and which are used for diagnosis, screening, monitoring,
surveillance, or for providing predictive or prognostic information
are included in the NCCN Biomarkers Compendium.
General information on appropriate methodologies for
biomarker testing is provided, focusing on the biology or
abnormality being measured rather than on commercially
available tests or test kits. NCCN anticipates that this
compendium may eventually be used by payers in much the
same way the NCCN Compendium is utilized as a reference
for coverage decisions. The NCCN Biomarkers Compendium
aims to ensure that patients have coverage and access to
appropriate biomarker testing based on the evaluations and
recommendations of NCCN Guidelines Panel members.
Available electronically on NCCN.org, the NCCN Biomarkers
Compendium is updated in conjunction with the NCCN
Guidelines on a continual basis.
NCCN Drugs & Biologics Compendium
The NCCN Compendium
, derived directly from the NCCN
Guidelines, is designed to support decision-making regarding
the appropriate use of drugs and biologics in patients with
cancer. The uses identified are based upon evaluation of
scientific literature integrated with expert judgment. Indicated
uses are categorized in a systematic approach that describes
the type of evidence available for and the degree of consensus
underlying each recommendation. All recommendations (at
all category levels) in the NCCN Compendium represent
appropriate, medically necessary care. The NCCN
Compendium lists both FDA-approved uses and appropriate
uses beyond the FDA indication.
The NCCN Compendium is recognized by public and private
insurers alike, including, but not limited to, the Centers for
Medicare & Medicaid Services (CMS) and UnitedHealthcare,
as an authoritative reference for oncology coverage policy.
Managed care medical directors, pharmacy benefits directors,
and other health care professionals reference the NCCN
Compendium when making decisions that impact patient
access to appropriate therapy.
Available electronically on NCCN.org, the NCCN Compendium
is updated in conjunction with the NCCN Guidelines on a
Access the NCCN Compendium
Access the NCCN Biomarkers Compendium